Secukinumab Shows Higher Symptomatic Improvement and Lower Cost Per Response vs. Adalimumab After One Year Treatment of Active Ankylosing Spondylitis- A Cost Per Responder Analysis from A Chilean Perspective
Abstract
Authors
R Rojas M Barbeau SM Jugl A MacPherson